|
 |
About Critical Path
The Critical Path Initiative is FDA's effort
to stimulate and facilitate a national effort to modernize
the scientific process through which a potential human drug,
biological product, or medical device is transformed from a
discovery or "proof
of concept" into a medical product. More.
Critical Path Opportunities
Reports
Contact Information
FDA's Office of Critical Path Programs
Dr. Rachel Behrman, Director
Dr. Leonard Sacks, Deputy Director
Phone: 301-827-1512
Fax: 301-443-9718
Contact Us
|
|
|
|
Upcoming Events
Articles of Interest
Past Events
- Science Writers Symposium, November 10, 2008
- Critical Path Workshop on
Clinical Trials for Local Treatment of Breast Cancer by Thermal Ablation,
September 15, 2008 New! Transcript (PDF, 709KB)
- Critical
Path on the Move, DIA meeting, September 15 and 16, 2008
- Artificial pancreas
public workshop, July 21-22, 2008
- Public Hearing on
Antimicrobial Resistance, April 28, 2008
- Public Workshop
on Draft Guidance, Developing Coronary Drug Eluting Stents, April 29, 2008
- Workshop on In Vitro Analyses of Cell/Scaffold Products, Dec. 6-7, 2007
- Workshop on Improving the Quality of Cancer Clinical Trials, Oct. 4-5, 2007
- Accelerating Anticancer Agent Development and Validation
Workshop, June 20-22, 2007
- FDA
Commissioner testifying on Critical Path at the University
of Utah --, June 1, 2007
- BIMO
Workshop, May 10-11, 2007
- Public
Hearing: Should prescribing information be distributed
electronically?-- April 27, 2007
- Hepatotoxicity
Special Interest Group: Issues and Controversies in Drug-Induced
Liver Injury (DILI), January 24 and 25, 2007
- Part
15 hearing - Electronic Submission of Regulatory Information,
Dec. 18, 2006
- Sex Differences
and Critical Path Initiative, Nov. 13, 2006
- Part 15 hearing
- Conduct of Emergency Clinical Research, Oct. 11, 2006
|
|
|
|
|
|
